FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• ChenYSChenJGZhuJZhangYHDingLLLong-term survival trends of gastric cancer patients between 1972 and 2011 in QidongChin J Cancer2015341260260726481511
   PubMedGoogle Scholar
• QiuMZXuRHThe progress of targeted therapy in advanced gastric cancerBiomark Res2013113224330856
   PubMedGoogle Scholar
• FuchsCSTomasekJYongCJREGARD Trial InvestigatorsRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialLancet20143839911313924094768
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKVan CutsemERAINBOW Study GroupRamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaAToGA Trial InvestigatorsTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• GorenDHorowitzATZalipskySWoodleMCYardenYGabizonATargeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studiesBr J Cancer19967411174917568956788
   PubMed Web of Science ®Google Scholar
• Yamashita-KashimaYIijimaSYorozuKPertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft modelsClin Cancer Res20111755060507021700765
   PubMedGoogle Scholar
• QiuMZLiQWangZQHER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observationInt J Cancer2014134102468247724155030
   PubMed Web of Science ®Google Scholar
• SatohTXuRHChungHCLapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN a randomized, phase III studyJ Clin Oncol201432192039204924868024
   PubMed Web of Science ®Google Scholar
• VoskensCJWatanabeRRollinsSCampanaDHasumiKMannDLEx-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicityJ Exp Clin Cancer Res20102913420937115
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsNat Med20006444344610742152
   PubMed Web of Science ®Google Scholar
• WarmerdamPAvan de WinkelJGGosselinEJCapelPJMolecular basis for a polymorphism of human Fc gamma receptor II (CD32)J Exp Med1990172119252141627
   PubMedGoogle Scholar
• StavenhagenJBGorlatovSTuaillonNFc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptorsCancer Res200767188882889017875730
   PubMed Web of Science ®Google Scholar
• KoeneHRKleijerMAlgraJRoosDvon DemBAde HaasMFc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotypeBlood1997903110911149242542
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood200299375475811806974
   PubMed Web of Science ®Google Scholar
• ZhangWGordonMSchultheisAMFCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximabJ Clin Oncol200725243712371817704420
   PubMed Web of Science ®Google Scholar
• BibeauFLopez-CrapezEDi FioreFImpact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecanJ Clin Oncol20092771122112919164213
   PubMed Web of Science ®Google Scholar
• TamuraKShimizuCHojoTFcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancerAnn Oncol20112261302130721109570
   PubMedGoogle Scholar
• HurvitzSABettingDJSternHMAnalysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsClin Cancer Res201218123478348622504044
   PubMedGoogle Scholar
• MusolinoANaldiNBortesiBImmunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancerJ Clin Oncol200826111789179618347005
   PubMed Web of Science ®Google Scholar
• NortonNOlsonRMPegramMAssociation studies of Fcgamma receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831Cancer Immunol Res201421096296924989892
   PubMed Web of Science ®Google Scholar
• BoeroSMorabitoABanelliBAnalysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcgammaRIIIA/FcgammaRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell linesJ Transl Med20151332426450443
   PubMed Web of Science ®Google Scholar
• PetricevicBLaengleJSingerJTrastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsJ Transl Med20131130724330813
   PubMed Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
   PubMed Web of Science ®Google Scholar